Abstract

ASCENTAGE PHARMA GROUP is scheduled to release quarterly results on August 19, 2026 Pre-Mkt, and consensus points to faster top-line growth with narrowing per-share losses as its commercialization engine gains traction.

Market Forecast

Consensus indicates ASCENTAGE PHARMA GROUP is set to deliver approximately 367.03 million RMB in revenue this quarter, up 58.18% year over year, with adjusted EPS around -0.26 and EBIT near -843.45 million RMB; the company has not issued quantifiable guidance for gross margin or net margin. The mix is expected to remain anchored by the commercial “Products” franchise, with margin resilience supported by product economics and operating leverage as scale improves. Olverembatinib continues to represent the most promising driver, underpinning the forecast 58.18% revenue growth and aligning with the “Products” category that generated 499.27 million RMB last quarter.

Last Quarter Review

ASCENTAGE PHARMA GROUP reported revenue of 574.12 million RMB last quarter, a gross profit margin of 91.98%, GAAP net profit attributable to the parent company of -326.00 million RMB, a net profit margin of -191.53%, and adjusted EPS of -0.99. A notable financial highlight was that the quarter-on-quarter change in net profit was approximately flat, indicating that operating losses were broadly stable sequentially even as commercialization spending continued. Within operations, the “Products” segment contributed 499.27 million RMB and “Others” contributed 74.85 million RMB; this revenue mix dovetails with the company’s ongoing commercial ramp that accelerated through 2025 and into 2026, with company-level growth momentum evidenced by the robust outlook into the current quarter.

Current Quarter Outlook

Main commercial operations

The core commercial franchise, reflected in the “Products” segment, remains the principal engine of the quarter. This business is expected to sustain a high gross margin profile, consistent with the 91.98% result last quarter, while the key swing factor is operating leverage as selling, general, and R&D expenses normalize relative to the expanding revenue base. With consensus revenue at approximately 367.03 million RMB for the quarter and adjusted EPS improving to about -0.26, the operating line should be supported by higher volumes and continued price discipline where applicable. Sequentially, management’s spending cadence appears to be tightening versus earlier ramp phases, which—combined with scale—should help narrow per-share losses despite ongoing investment in market access, medical affairs, and patient services.

The expected 58.18% year-over-year revenue increase this quarter implies solid uptake and broader geographic penetration for the portfolio. This also means logistics, channel inventory, and reimbursement timing will matter for reported revenue recognition. Historically high gross margins suggest the cost of goods sold will remain a secondary factor in variability relative to the pace of launch and commercial execution. Where revenue lands within the implied range will likely depend on real-world persistency and new patient starts during the quarter, both of which feed through to sequential revenue progression and cash conversion.

Given last quarter’s flat quarter-on-quarter net profit change and the current EBIT expectation of about -843.45 million RMB, investors will look for evidence of opex discipline. Indicators to monitor on the call include commentary on salesforce productivity, medical-science liaison deployment, and any updates on access contracts that can improve pull-through and reduce friction at the point of care. The balance between funding pipeline milestones and realizing operating leverage in the base business remains central to the near-term trajectory.

Most promising growth driver

Olverembatinib continues to be the standout growth driver, supported by expanding clinical and commercial evidence and the company’s organizational push to scale its presence. For context, the brand anchored a material share of the portfolio in 2025, and ongoing physician education and label expansion efforts are positioned to lift its contribution in 2026. The current quarter’s consolidated revenue forecast of 367.03 million RMB, up 58.18% year over year, implicitly relies on continued uptake for olverembatinib as the primary contributor to aggregate growth.

Commercial execution steps taken midyear reinforce this thesis. The company appointed senior leaders to oversee global business development and to build commercial operations outside Greater China, signaling a more coordinated route-to-market and a tighter interface between development, partnering, and launch readiness. These appointments point to faster decision cycles on distribution, pricing, and reimbursement submissions—levers that can translate into higher realized revenue and improved predictability of quarterly run rates. The near-term effect should be most visible in physician reach and the conversion of clinical data into everyday prescribing, especially as conference exposure and medical education programs compound.

On the economics, olverembatinib’s product profile supports the group’s strong gross margin. As volumes rise, manufacturing absorption and supply chain efficiencies should offer incremental tailwinds to unit costs. The primary offset remains operating expenses tied to market expansion and lifecycle management; however, as top-line scale accelerates, the effect on per-share losses should diminish, consistent with the expected improvement in adjusted EPS to around -0.26 this quarter.

What will drive the stock this quarter

- Delivery versus the 58.18% revenue growth bogey: Hitting or exceeding the implied revenue mark near 367.03 million RMB is the first-order determinant for the shares into and immediately after the print. A revenue beat, coupled with a less negative EBIT trajectory than the -843.45 million RMB consensus, would reinforce the margin-improvement narrative and support the valuation framework that implies continued commercialization traction.

- Visibility on operating leverage: Investors will parse commentary on selling and medical spend intensity, hiring cadence, and patient support program costs. Evidence that the company can expand revenue while curbing the growth in operating expenses will be a key positive for the path to breakeven. Any quantification of salesforce productivity gains or lower cost-to-serve per patient would strengthen confidence that adjusted EPS can continue to improve quarter over quarter.

- Commercial infrastructure and partnerships: The leadership hires for business development and commercial operations outside Greater China raise expectations for a smoother global rollout path. Specifics on distribution arrangements, inventory and channel health, and the timing of new market entries or label expansions will likely be taken as leading indicators of next-quarter revenue. Clear milestones can help investors map the ramp and reduce the perceived volatility of quarterly results.

- Scientific and medical momentum: The company’s recent data presentations at major medical meetings enhance physician awareness and can lift real-world adoption. Any updates on clinical progress that reinforce differentiation may sustain a favorable prescribing trend, even in the absence of formal guidance on margins. This is particularly relevant to the durability of the growth rate beyond the current quarter.

- FX and reporting structure: While the revenue outlook is presented in RMB for the dual-listed entity, the ADR framework and cost bases across jurisdictions can introduce translation effects into per-share metrics. Investors will watch for management’s comments on currency exposure, cash deployment across regions, and any structural steps to align revenue and cost currencies, as these can modestly influence reported EPS.

Analyst Opinions

Bullish views dominate the preview period. Based on the collected commentary, the ratio of bullish to bearish opinions is 100% to 0%, with institutions highlighting both the growth momentum and improving loss profile. Piper Sandler reaffirmed a Buy rating on ASCENTAGE PHARMA GROUP’s ADR, emphasizing the strengthening commercialization trend and the company’s execution against its revenue ramp. B. Riley initiated coverage at Buy with a 45-dollar price target, citing the combination of robust top-line growth expectations and a pathway to margin improvement as the quarter progresses.

The bullish case centers on three pillars. First, the 58.18% year-over-year revenue growth expectation to approximately 367.03 million RMB this quarter establishes a high but credible bar that reflects real uptake across the portfolio. Second, adjusted EPS projected around -0.26 implies a 73.17% year-over-year improvement, an important signal that operating leverage is beginning to show through after multiple periods of investment in commercial capabilities and medical affairs. Third, consensus expects EBIT near -843.45 million RMB, reflecting heavy ongoing investment, but analysts look for sequential improvements tied to scaling revenues and tighter cost control—both of which can compress losses through the remainder of the year.

Analysts also point to recent organizational steps that should enhance execution, including the build-out of commercial leadership for markets outside Greater China and a coordinated approach to business development. These moves are seen as enabling faster decisions on market entry, distribution, and access, which can translate into more predictable quarterly revenue and a smoother ramp in new geographies. The accumulation of clinical data showcased at major scientific meetings is viewed as a commercial asset, supporting physician engagement and adoption curves without necessitating deep discounting or materially higher promotional intensity.

In assessing risk-reward into the print, the majority view holds that the revenue trajectory and EPS improvement are sufficiently visible to support a constructive stance. The core debate is not whether revenue grows, but whether the company can pair top-line beats with increasingly efficient operating spending so that the slope of EBIT and EPS improves quarter by quarter. If management provides evidence of rising salesforce productivity and durable patient persistency, alongside clearer timelines for new market contributions, bulls see scope for positive estimate revisions. With consensus already embedding 58.18% revenue growth, the stock’s reaction will likely hinge on whether reported revenue and the operating line meet or exceed these levels and on management’s commentary about sustaining momentum into the next quarter.